Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters
Jason Chen, Jonathan Pan, Tingting Zhan, Sherilyn Tuazon, Neeraj Saini, William O'Hara, Joanne Filicko-O'Hara, Thomas Klumpp, Margaret Kasner, Matthew Carabasi, Pierluigi Porcu, John L Wagner, Jason Chen, Jonathan Pan, Tingting Zhan, Sherilyn Tuazon, Neeraj Saini, William O'Hara, Joanne Filicko-O'Hara, Thomas Klumpp, Margaret Kasner, Matthew Carabasi, Pierluigi Porcu, John L Wagner
Abstract
Engraftment syndrome (ES) is a known complication of autologous hematopoietic stem cell transplant during neutrophil recovery. There is a limited amount of data available comparing the incidence of ES with post-transplant granulocyte colony-stimulating factor versus granulocyte macrophage colony-stimulating factor (GM-CSF), specifically in patients with multiple myeloma. Our retrospective review of 156 patients at a single center showed that GM-CSF was associated with a higher incidence of ES compared with G-CSF (32% versus 8% of patients, P < .001) and that development of ES was associated with a 32.9% (P < .001) longer hospital stay. This suggests that the choice of growth factor could possibly contribute to the development of ES and the associated costs of increased medical care.
Keywords: Autologous; Engraftment syndrome; Growth factor; Multiple myeloma; Stem cell transplant.
Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Source: PubMed